Search

Your search keyword '"Merrick, I"' showing total 1,879 results
Start Over Author "Merrick, I"
1,879 results on '"Merrick, I"'

2. Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma

Author

Sydney A. Keatts, Aya F. Salem, David M. Swanson, Ahsan S. Farooqi, Andrew J. Bishop, Rodabe N. Amaria, Jennifer L. McQuade, Isabella C. Glitza Oliva, Adi Diab, Roi Weiser, Sarah B. Fisher, Ryan P. Goepfert, Merrick I. Ross, B. Ashleigh Guadagnolo, and Devarati Mitra

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background and purpose: As patients with advanced melanoma live longer in the context of systemic therapy advancements, better strategies for durable control of bulky tumors are needed. In this study, we evaluated if dose-escalated hypofractionated radiation therapy (HFRT) can provide durable local control and improve tumor-associated symptoms in patients with unresectable or bulky metastatic melanoma for whom stereotactic ablative radiotherapy (RT) approaches are not feasible due to tumor size or location. Materials and methods: We retrospectively reviewed 49 patients with unresectable or bulky metastatic melanoma who were treated to a total of 53 tumor targets with 12–17 fractions HFRT at our institution between 2015–2022. Clinical scenarios included: unresectable, locoregional only disease (26 %); oligometastatic disease (5 known sites of disease or with at least 3 sites progressing, 40 %). Results: Of the 53 HFRT targets, 91 % (n = 48) had radiographic evidence of response as defined by either stabilization (6 %, n = 3), decreased size (74 %, n = 39), or decreased FDG avidity (11 %, n = 6). Of the 43 symptomatic patients, 98 % (n = 42) had symptomatic improvement. One −year local control was 79 %, with 2-year progression-free and overall survival of 33 % and 39 % respectively. The most common acute toxicities were radiation dermatitis (16 %, n = 8) or a pain flare (14 %, n = 7). Late toxicities were uncommon and typically grade 1. Conclusion: HFRT provides favorable local control and symptomatic relief with limited toxicity in tumors not amenable to surgical resection or stereotactic ablative RT.

Published
2024
Full Text
View/download PDF

3. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Author

Patel, Sapna P, Othus, Megan, Chen, Yuanbin, Wright, G Paul, Yost, Kathleen J, Hyngstrom, John R, Hu-Lieskovan, Siwen, Lao, Christopher D, Fecher, Leslie A, Truong, Thach-Giao, Eisenstein, Jennifer L, Chandra, Sunandana, Sosman, Jeffrey A, Kendra, Kari L, Wu, Richard C, Devoe, Craig E, Deutsch, Gary B, Hegde, Aparna, Khalil, Maya, Mangla, Ankit, Reese, Amy M, Ross, Merrick I, Poklepovic, Andrew S, Phan, Giao Q, Onitilo, Adedayo A, Yasar, Demet G, Powers, Benjamin C, Doolittle, Gary C, In, Gino K, Kokot, Niels, Gibney, Geoffrey T, Atkins, Michael B, Shaheen, Montaser, Warneke, James A, Ikeguchi, Alexandra, Najera, Jose E, Chmielowski, Bartosz, Crompton, Joseph G, Floyd, Justin D, Hsueh, Eddy, Margolin, Kim A, Chow, Warren A, Grossmann, Kenneth F, Dietrich, Eliana, Prieto, Victor G, Lowe, Michael C, Buchbinder, Elizabeth I, Kirkwood, John M, Korde, Larissa, Moon, James, Sharon, Elad, Sondak, Vernon K, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Patient Safety, Cancer, Clinical Research, 6.1 Pharmaceuticals, 6.4 Surgery, Humans, Adjuvants, Immunologic, Disease Progression, Melanoma, Neoadjuvant Therapy, Skin Neoplasms, Antineoplastic Agents, Immunological, Chemotherapy, Adjuvant, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundWhether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown.MethodsIn a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses) for approximately 1 year or until disease recurred or unacceptable toxic effects developed (adjuvant-only group). The primary end point was event-free survival in the intention-to-treat population. Events were defined as disease progression or toxic effects that precluded surgery; the inability to resect all gross disease; disease progression, surgical complications, or toxic effects of treatment that precluded the initiation of adjuvant therapy within 84 days after surgery; recurrence of melanoma after surgery; or death from any cause. Safety was also evaluated.ResultsAt a median follow-up of 14.7 months, the neoadjuvant-adjuvant group (154 patients) had significantly longer event-free survival than the adjuvant-only group (159 patients) (P = 0.004 by the log-rank test). In a landmark analysis, event-free survival at 2 years was 72% (95% confidence interval [CI], 64 to 80) in the neoadjuvant-adjuvant group and 49% (95% CI, 41 to 59) in the adjuvant-only group. The percentage of patients with treatment-related adverse events of grades 3 or higher during therapy was 12% in the neoadjuvant-adjuvant group and 14% in the adjuvant-only group.ConclusionsAmong patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. (Funded by the National Cancer Institute and Merck Sharp and Dohme; S1801 ClinicalTrials.gov number, NCT03698019.).

Published
2023

5. Neoadjuvant relatlimab and nivolumab in resectable melanoma

Author

Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tezlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, and Tawbi, Hussein A.

Published
2022
Full Text
View/download PDF

7. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Author

Khattak, Muhammad A., Luke, Jason J., Long, Georgina V., Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Robert, Caroline, Grob, Jean-Jacques, de la Cruz Merino, Luis, Del Vecchio, Michele, Spagnolo, Francesco, Mackiewicz, Jacek, Chiarion-Sileni, Vanna, Carlino, Matteo S., Mohr, Peter, De Galitiis, Federica, Ross, Merrick I., Eroglu, Zeynep, Chen, Ke, Jiang, Ruixuan, Fukunaga-Kalabis, Mizuho, Krepler, Clemens, Eggermont, Alexander M.M., and Kirkwood, John M.

Published
2022
Full Text
View/download PDF

9. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2022
Full Text
View/download PDF

10. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Author

van Akkooi, Alexander C. J., Hieken, Tina J., Burton, Elizabeth M., Ariyan, Charlotte, Ascierto, Paolo A., Asero, Salvatore V. M. A., Blank, Christian U., Block, Matthew S., Boland, Genevieve M., Caraco, Corrado, Chng, Sydney, Davidson, B. Scott, Duprat Neto, Joao Pedreira, Faries, Mark B., Gershenwald, Jeffrey E., Grunhagen, Dirk J., Gyorki, David E., Han, Dale, Hayes, Andrew J., van Houdt, Winan J., Karakousis, Giorgos C., Klop, Willem M. C., Long, Georgina V., Lowe, Michael C., Menzies, Alexander M., Olofsson Bagge, Roger, Pennington, Thomas E., Rutkowski, Piotr, Saw, Robyn P. M., Scolyer, Richard A., Shannon, Kerwin F., Sondak, Vernon K., Tawbi, Hussein, Testori, Alessandro A. E., Tetzlaff, Mike T., Thompson, John F., Zager, Jonathan S., Zuur, Charlotte L., Wargo, Jennifer A., Spillane, Andrew J., and Ross, Merrick I.

Published
2022
Full Text
View/download PDF

11. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Author

Megumi Kai, Angela N. Marx, Diane D. Liu, Yu Shen, Hui Gao, James M. Reuben, Gary Whitman, Savitri Krishnamurthy, Merrick I. Ross, Jennifer K. Litton, Bora Lim, Nuhad Ibrahim, Takahiro Kogawa, and Naoto T. Ueno

Subjects
Medicine, Science
Abstract

Abstract Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 106 PFU/mL on day 1 (cycle 1), 108 PFU/mL on day 22 (cycle 2), and 108 PFU/mL every 2 weeks thereafter (cycles ≥ 3). Nine patients were enrolled, 6 with only locoregional disease and 3 with both locoregional and distant disease. No patient completed the planned 10 cycles or achieved complete or partial response. The median number of cycles administered was 4 (range, 3–8). Seven patients withdrew prematurely because of uncontrolled disease progression, 1 withdrew after cycle 3 because of fatigue, and 1 withdrew after cycle 4 for reasons unrelated to study treatment. Median progression-free survival and overall survival were 77 days (95% CI, 63–NA) and 361 days (95% CI, 240–NA). Two patients received 8 cycles with clinically stable disease as the best response. The most common grade 2 or higher adverse event was injection site reaction (n = 7, 78%). Future studies could examine whether combining intratumoral T-VEC with concurrent systemic therapy produces better outcomes.

Published
2021
Full Text
View/download PDF

13. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients

Author

Keung, Emily Z., Amaria, Rodabe N., Sondak, Vernon K., Ross, Merrick I., Kirkwood, John M., Wargo, Jennifer A., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

15. Treatment of Primary Melanomas

Author

Thompson, John F., Henderson, Michael A., Williams, Gabrielle, Ross, Merrick I., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

17. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Author

Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tetzlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, and Tawbi, Hussein A.

Published
2023
Full Text
View/download PDF

18. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features

Author

Nagarajan, Priyadharsini, Piao, Jin, Ning, Jing, Noordenbos, Laura E., Curry, Jonathan L., Torres-Cabala, Carlos A., Diwan, A.Hafeez, Ivan, Doina, Aung, Phyu P., Ross, Merrick I., Royal, Richard E., Wargo, Jennifer A., Wang, Wei-Lien, Samdani, Rashmi, Lazar, Alexander J., Rashid, Asif, Davies, Michael A., Prieto, Victor G., Gershenwald, Jeffrey E., and Tetzlaff, Michael T.

Published
2020
Full Text
View/download PDF

20. Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature review

Author

Salah, Haneen T., primary, Yang, Richard K., additional, Roy‐Chowdhuri, Sinchita, additional, Ross, Merrick I., additional, Aung, Phyu P., additional, Rothrock, Aimi T., additional, Torres‐Cabala, Carlos A., additional, Curry, Jonathan L., additional, Prieto, Victor G., additional, Nagarajan, Priyadharsini, additional, and Cho, Woo Cheal, additional

Published
2024
Full Text
View/download PDF

21. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Author

van Akkooi, Alexander C. J., Hieken, Tina J., Burton, Elizabeth M., Ariyan, Charlotte, Ascierto, Paolo A., Asero, Salvatore V. M. A., Blank, Christian U., Block, Matthew S., Boland, Genevieve M., Caraco, Corrado, Chng, Sydney, Davidson, B. Scott, Duprat Neto, Joao Pedreira, Faries, Mark B., Gershenwald, Jeffrey E., Grunhagen, Dirk J., Gyorki, David E., Han, Dale, Hayes, Andrew J., van Houdt, Winan J., Karakousis, Giorgos C., Klop, Willem M. C., Long, Georgina V., Lowe, Michael C., Menzies, Alexander M., Bagge, Roger Olofsson, Pennington, Thomas E., Rutkowski, Piotr, Saw, Robyn P. M., Scolyer, Richard A., Shannon, Kerwin F., Sondak, Vernon K., Tawbi, Hussein, Testori, Alessandro A. E., Tetzlaff, Mike T., Thompson, John F., Zager, Jonathan S., Zuur, Charlotte L., Wargo, Jennifer A., Spillane, Andrew J., and Ross, Merrick I.

Published
2022
Full Text
View/download PDF

22. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2023
Full Text
View/download PDF

24. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

25. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Author

Amaria, Rodabe N, Prieto, Peter A, Tetzlaff, Michael T, Reuben, Alexandre, Andrews, Miles C, Ross, Merrick I, Glitza, Isabella C, Cormier, Janice, Hwu, Wen-Jen, Tawbi, Hussein A, Patel, Sapna P, Lee, Jeffrey E, Gershenwald, Jeffrey E, Spencer, Christine N, Gopalakrishnan, Vancheswaran, Bassett, Roland, Simpson, Lauren, Mouton, Rosalind, Hudgens, Courtney W, Zhao, Li, Zhu, Haifeng, Cooper, Zachary A, Wani, Khalida, Lazar, Alexander, Hwu, Patrick, Diab, Adi, Wong, Michael K, McQuade, Jennifer L, Royal, Richard, Lucci, Anthony, Burton, Elizabeth M, Reddy, Sangeetha, Sharma, Padmanee, Allison, James, Futreal, Phillip A, Woodman, Scott E, Davies, Michael A, and Wargo, Jennifer A

Published
2018
Full Text
View/download PDF

26. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Author

Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, and Antoni Ribas

Subjects
General Medicine
Published
2023
Full Text
View/download PDF

27. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

Author

Ribas, Antoni, Camacho, Luis H, Lee, Sun, Hersh, Evan M, Brown, Charles K, Richards, Jon M, Rodriguez, Maria, Prieto, Victor G, Glaspy, John A, Oseguera, Denise K, Hernandez, Jackie, Villanueva, Arturo, Chmielowski, Bartosz, Mitsky, Peggie, Bercovici, Nadège, Wasserman, Ernesto, Landais, Didier, and Ross, Merrick I

Abstract

Abstract Background Several single center studies have provided evidence of immune activation and antitumor activity of therapeutic vaccination with dendritic cells (DC) in patients with metastatic melanoma. The efficacy of this approach in patients with favorable prognosis metastatic melanoma limited to the skin, subcutaneous tissues and lung (stages IIIc, M1a, M1b) was tested in a multicenter two stage phase 2 study with centralized DC manufacturing. Methods The vaccine (IDD-3) consisted 8 doses of autologous monocyte-derived matured DC generated in serum-free medium with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-13 (IL-13), pulsed with lysates of three allogeneic melanoma cell lines, and matured with interferon gamma. The primary endpoint was antitumor activity. Results Among 33 patients who received IDD-3 there was one complete response (CR), two partial responses (PR), and six patients had stable disease (SD) lasting more than eight weeks. The overall prospectively defined tumor growth control rate was 27% (90% confidence interval of 13-46%). IDD-3 administration had minimal toxicity and it resulted in a high frequency of immune activation to immunizing melanoma antigens as assessed by in vitro immune monitoring assays. Conclusions The administration of matured DC loaded with tumor lysates has significant immunogenicity and antitumor activity in patients with limited metastatic melanoma. Clinical trial registration NCT00107159.

Published
2010

29. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Author

Amaria, Rodabe N., Reddy, Sangeetha M., Tawbi, Hussein A., Davies, Michael A., Ross, Merrick I., Glitza, Isabella C., Cormier, Janice N., Lewis, Carol, Hwu, Wen-Jen, Hanna, Ehab, Diab, Adi, Wong, Michael K., Royal, Richard, Gross, Neil, Weber, Randal, Lai, Stephen Y., Ehlers, Richard, Blando, Jorge, Milton, Denái R., Woodman, Scott, Kageyama, Robin, Wells, Daniel K., Hwu, Patrick, Patel, Sapna P., Lucci, Anthony, Hessel, Amy, Lee, Jeffrey E., Gershenwald, Jeffrey, Simpson, Lauren, Burton, Elizabeth M., Posada, Liberty, Haydu, Lauren, Wang, Linghua, Zhang, Shaojun, Lazar, Alexander J., Hudgens, Courtney W., Gopalakrishnan, Vancheswaran, Reuben, Alexandre, Andrews, Miles C., Spencer, Christine N., Prieto, Victor, Sharma, Padmanee, Allison, James, Tetzlaff, Michael T., and Wargo, Jennifer A.

Published
2018
Full Text
View/download PDF

34. Supplementary Table 3 - 4 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Radvanyi, Laszlo G., primary, Bernatchez, Chantale, primary, Zhang, Minying, primary, Fox, Patricia S., primary, Miller, Priscilla, primary, Chacon, Jessica, primary, Wu, Richard, primary, Lizee, Gregory, primary, Mahoney, Sandy, primary, Alvarado, Gladys, primary, Glass, Michelle, primary, Johnson, Valen E., primary, McMannis, John D., primary, Shpall, Elizabeth, primary, Prieto, Victor, primary, Papadopoulos, Nicholas, primary, Kim, Kevin, primary, Homsi, Jade, primary, Bedikian, Agop, primary, Hwu, Wen-Jen, primary, Patel, Sapna, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Davies, Michael A., primary, Mansaray, Rahmatu, primary, Fulbright, Orenthial J., primary, Toth, Christopher, primary, Ramachandran, Renjith, primary, Wardell, Seth, primary, Gonzalez, Audrey, primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

35. Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Author

Slingluff, Craig L., primary, Petroni, Gina R., primary, Olson, Walter C., primary, Smolkin, Mark E., primary, Ross, Merrick I., primary, Haas, Naomi B., primary, Grosh, William W., primary, Boisvert, Marc E., primary, Kirkwood, John M., primary, and Chianese-Bullock, Kimberly A., primary

Published
2023
Full Text
View/download PDF

36. Supplemental Table 2. Distribution of primary vulvar melanomas with tumor thickness > 4.00 mm reported in literature. from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases

Author

Nagarajan, Priyadharsini, primary, Curry, Jonathan L., primary, Ning, Jing, primary, Piao, Jin, primary, Torres-Cabala, Carlos A., primary, Aung, Phyu P., primary, Ivan, Doina, primary, Ross, Merrick I., primary, Levenback, Charles F., primary, Frumovitz, Michael, primary, Gershenwald, Jeffrey E., primary, Davies, Michael A., primary, Malpica, Anais, primary, Prieto, Victor G., primary, and Tetzlaff, Michael T., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 2 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Radvanyi, Laszlo G., primary, Bernatchez, Chantale, primary, Zhang, Minying, primary, Fox, Patricia S., primary, Miller, Priscilla, primary, Chacon, Jessica, primary, Wu, Richard, primary, Lizee, Gregory, primary, Mahoney, Sandy, primary, Alvarado, Gladys, primary, Glass, Michelle, primary, Johnson, Valen E., primary, McMannis, John D., primary, Shpall, Elizabeth, primary, Prieto, Victor, primary, Papadopoulos, Nicholas, primary, Kim, Kevin, primary, Homsi, Jade, primary, Bedikian, Agop, primary, Hwu, Wen-Jen, primary, Patel, Sapna, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Davies, Michael A., primary, Mansaray, Rahmatu, primary, Fulbright, Orenthial J., primary, Toth, Christopher, primary, Ramachandran, Renjith, primary, Wardell, Seth, primary, Gonzalez, Audrey, primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 1 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Radvanyi, Laszlo G., primary, Bernatchez, Chantale, primary, Zhang, Minying, primary, Fox, Patricia S., primary, Miller, Priscilla, primary, Chacon, Jessica, primary, Wu, Richard, primary, Lizee, Gregory, primary, Mahoney, Sandy, primary, Alvarado, Gladys, primary, Glass, Michelle, primary, Johnson, Valen E., primary, McMannis, John D., primary, Shpall, Elizabeth, primary, Prieto, Victor, primary, Papadopoulos, Nicholas, primary, Kim, Kevin, primary, Homsi, Jade, primary, Bedikian, Agop, primary, Hwu, Wen-Jen, primary, Patel, Sapna, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Davies, Michael A., primary, Mansaray, Rahmatu, primary, Fulbright, Orenthial J., primary, Toth, Christopher, primary, Ramachandran, Renjith, primary, Wardell, Seth, primary, Gonzalez, Audrey, primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure and Supplementary Tables from Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

Author

Forget, Marie-Andrée, primary, Haymaker, Cara, primary, Hess, Kenneth R., primary, Meng, Yuzhong Jeff, primary, Creasy, Caitlin, primary, Karpinets, Tatiana, primary, Fulbright, Orenthial J., primary, Roszik, Jason, primary, Woodman, Scott E., primary, Kim, Young Uk, primary, Sakellariou-Thompson, Donastas, primary, Bhatta, Ankit, primary, Wahl, Arely, primary, Flores, Esteban, primary, Thorsen, Shawne T., primary, Tavera, René J., primary, Ramachandran, Renjith, primary, Gonzalez, Audrey M., primary, Toth, Christopher L., primary, Wardell, Seth, primary, Mansaray, Rahmatu, primary, Patel, Vruti, primary, Carpio, Destiny Joy, primary, Vaughn, Carol, primary, Farinas, Chantell M., primary, Velasquez, Portia G., primary, Hwu, Wen-Jen, primary, Patel, Sapna P., primary, Davies, Michael A., primary, Diab, Adi, primary, Glitza, Isabella C., primary, Tawbi, Hussein, primary, Wong, Michael K., primary, Cain, Suzanne, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Wargo, Jennifer A., primary, Radvanyi, Laszlo G., primary, Torres-Cabala, Carlos A., primary, Beroukhim, Rameen, primary, Hwu, Patrick, primary, Amaria, Rodabe N., primary, and Bernatchez, Chantale, primary

Published
2023
Full Text
View/download PDF

40. CCR Translation for the Article from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Author

Slingluff, Craig L., primary, Petroni, Gina R., primary, Olson, Walter C., primary, Smolkin, Mark E., primary, Ross, Merrick I., primary, Haas, Naomi B., primary, Grosh, William W., primary, Boisvert, Marc E., primary, Kirkwood, John M., primary, and Chianese-Bullock, Kimberly A., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 5 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Radvanyi, Laszlo G., primary, Bernatchez, Chantale, primary, Zhang, Minying, primary, Fox, Patricia S., primary, Miller, Priscilla, primary, Chacon, Jessica, primary, Wu, Richard, primary, Lizee, Gregory, primary, Mahoney, Sandy, primary, Alvarado, Gladys, primary, Glass, Michelle, primary, Johnson, Valen E., primary, McMannis, John D., primary, Shpall, Elizabeth, primary, Prieto, Victor, primary, Papadopoulos, Nicholas, primary, Kim, Kevin, primary, Homsi, Jade, primary, Bedikian, Agop, primary, Hwu, Wen-Jen, primary, Patel, Sapna, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Davies, Michael A., primary, Mansaray, Rahmatu, primary, Fulbright, Orenthial J., primary, Toth, Christopher, primary, Ramachandran, Renjith, primary, Wardell, Seth, primary, Gonzalez, Audrey, primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figures 1 - 7 from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Radvanyi, Laszlo G., primary, Bernatchez, Chantale, primary, Zhang, Minying, primary, Fox, Patricia S., primary, Miller, Priscilla, primary, Chacon, Jessica, primary, Wu, Richard, primary, Lizee, Gregory, primary, Mahoney, Sandy, primary, Alvarado, Gladys, primary, Glass, Michelle, primary, Johnson, Valen E., primary, McMannis, John D., primary, Shpall, Elizabeth, primary, Prieto, Victor, primary, Papadopoulos, Nicholas, primary, Kim, Kevin, primary, Homsi, Jade, primary, Bedikian, Agop, primary, Hwu, Wen-Jen, primary, Patel, Sapna, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Davies, Michael A., primary, Mansaray, Rahmatu, primary, Fulbright, Orenthial J., primary, Toth, Christopher, primary, Ramachandran, Renjith, primary, Wardell, Seth, primary, Gonzalez, Audrey, primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Author

Slingluff, Craig L., primary, Petroni, Gina R., primary, Olson, Walter C., primary, Smolkin, Mark E., primary, Ross, Merrick I., primary, Haas, Naomi B., primary, Grosh, William W., primary, Boisvert, Marc E., primary, Kirkwood, John M., primary, and Chianese-Bullock, Kimberly A., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Figure Legend from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases

Author

Nagarajan, Priyadharsini, primary, Curry, Jonathan L., primary, Ning, Jing, primary, Piao, Jin, primary, Torres-Cabala, Carlos A., primary, Aung, Phyu P., primary, Ivan, Doina, primary, Ross, Merrick I., primary, Levenback, Charles F., primary, Frumovitz, Michael, primary, Gershenwald, Jeffrey E., primary, Davies, Michael A., primary, Malpica, Anais, primary, Prieto, Victor G., primary, and Tetzlaff, Michael T., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 1. Associations between clinical and histopathologic parameters are metastasis (Fisher's exact tests). from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases

Author

Nagarajan, Priyadharsini, primary, Curry, Jonathan L., primary, Ning, Jing, primary, Piao, Jin, primary, Torres-Cabala, Carlos A., primary, Aung, Phyu P., primary, Ivan, Doina, primary, Ross, Merrick I., primary, Levenback, Charles F., primary, Frumovitz, Michael, primary, Gershenwald, Jeffrey E., primary, Davies, Michael A., primary, Malpica, Anais, primary, Prieto, Victor G., primary, and Tetzlaff, Michael T., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Methods from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Radvanyi, Laszlo G., primary, Bernatchez, Chantale, primary, Zhang, Minying, primary, Fox, Patricia S., primary, Miller, Priscilla, primary, Chacon, Jessica, primary, Wu, Richard, primary, Lizee, Gregory, primary, Mahoney, Sandy, primary, Alvarado, Gladys, primary, Glass, Michelle, primary, Johnson, Valen E., primary, McMannis, John D., primary, Shpall, Elizabeth, primary, Prieto, Victor, primary, Papadopoulos, Nicholas, primary, Kim, Kevin, primary, Homsi, Jade, primary, Bedikian, Agop, primary, Hwu, Wen-Jen, primary, Patel, Sapna, primary, Ross, Merrick I., primary, Lee, Jeffrey E., primary, Gershenwald, Jeffrey E., primary, Lucci, Anthony, primary, Royal, Richard, primary, Cormier, Janice N., primary, Davies, Michael A., primary, Mansaray, Rahmatu, primary, Fulbright, Orenthial J., primary, Toth, Christopher, primary, Ramachandran, Renjith, primary, Wardell, Seth, primary, Gonzalez, Audrey, primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

48. Genomic Classification of Cutaneous Melanoma

Author

Akbani, Rehan, Akdemir, Kadir C., Aksoy, B. Arman, Albert, Monique, Ally, Adrian, Amin, Samirkumar B., Arachchi, Harindra, Arora, Arshi, Auman, J. Todd, Ayala, Brenda, Baboud, Julien, Balasundaram, Miruna, Balu, Saianand, Barnabas, Nandita, Bartlett, John, Bartlett, Pam, Bastian, Boris C., Baylin, Stephen B., Behera, Madhusmita, Belyaev, Dmitry, Benz, Christopher, Bernard, Brady, Beroukhim, Rameen, Bir, Natalie, Black, Aaron D., Bodenheimer, Tom, Boice, Lori, Boland, Genevieve M., Bono, Riccardo, Bootwalla, Moiz S., Bosenberg, Marcus, Bowen, Jay, Bowlby, Reanne, Bristow, Christopher A., Brockway-Lunardi, Laura, Brooks, Denise, Brzezinski, Jakub, Bshara, Wiam, Buda, Elizabeth, Burns, William R., Butterfield, Yaron S.N., Button, Michael, Calderone, Tiffany, Cappellini, Giancarlo Antonini, Carter, Candace, Carter, Scott L., Cherney, Lynn, Cherniack, Andrew D., Chevalier, Aaron, Chin, Lynda, Cho, Juok, Cho, Raymond J., Choi, Yoon-La, Chu, Andy, Chudamani, Sudha, Cibulskis, Kristian, Ciriello, Giovanni, Clarke, Amanda, Coons, Stephen, Cope, Leslie, Crain, Daniel, Curley, Erin, Danilova, Ludmila, D’Atri, Stefania, Davidsen, Tanja, Davies, Michael A., Delman, Keith A., Demchok, John A., Deng, Qixia A., Deribe, Yonathan Lissanu, Dhalla, Noreen, Dhir, Rajiv, DiCara, Daniel, Dinikin, Michael, Dubina, Michael, Ebrom, J. Stephen, Egea, Sophie, Eley, Greg, Engel, Jay, Eschbacher, Jennifer M., Fedosenko, Konstantin V., Felau, Ina, Fennell, Timothy, Ferguson, Martin L., Fisher, Sheila, Flaherty, Keith T., Frazer, Scott, Frick, Jessica, Fulidou, Victoria, Gabriel, Stacey B., Gao, Jianjiong, Gardner, Johanna, Garraway, Levi A., Gastier-Foster, Julie M., Gaudioso, Carmelo, Gehlenborg, Nils, Genovese, Giannicola, Gerken, Mark, Gershenwald, Jeffrey E., Getz, Gad, Gomez-Fernandez, Carmen, Gribbin, Thomas, Grimsby, Jonna, Gross, Benjamin, Guin, Ranabir, Gutschner, Tony, Hadjipanayis, Angela, Halaban, Ruth, Hanf, Benjamin, Haussler, David, Haydu, Lauren E., Hayes, D. Neil, Hayward, Nicholas K., Heiman, David I., Herbert, Lynn, Herman, James G., Hersey, Peter, Hoadley, Katherine A., Hodis, Eran, Holt, Robert A., Hoon, Dave SB., Hoppough, Susan, Hoyle, Alan P., Huang, Franklin W., Huang, Mei, Huang, Sharon, Hutter, Carolyn M., Ibbs, Matthew, Iype, Lisa, Jacobsen, Anders, Jakrot, Valerie, Janning, Alyssa, Jeck, William R., Jefferys, Stuart R., Jensen, Mark A., Jones, Corbin D., Jones, Steven J.M., Ju, Zhenlin, Kakavand, Hojabr, Kang, Hyojin, Kefford, Richard F., Khuri, Fadlo R., Kim, Jaegil, Kirkwood, John M., Klode, Joachim, Korkut, Anil, Korski, Konstanty, Krauthammer, Michael, Kucherlapati, Raju, Kwong, Lawrence N., Kycler, Witold, Ladanyi, Marc, Lai, Phillip H., Laird, Peter W., Lander, Eric, Lawrence, Michael S., Lazar, Alexander J., Łaźniak, Radoslaw, Lee, Darlene, Lee, Jeffrey E., Lee, Junehawk, Lee, Kenneth, Lee, Semin, Lee, William, Leporowska, Ewa, Leraas, Kristen M., Li, Haiyan I., Lichtenberg, Tara M., Lichtenstein, Lee, Lin, Pei, Ling, Shiyun, Liu, Jia, Liu, Ouida, Liu, Wenbin, Long, Georgina V., Lu, Yiling, Ma, Singer, Ma, Yussanne, Mackiewicz, Andrzej, Mahadeshwar, Harshad S., Malke, Jared, Mallery, David, Manikhas, Georgy M., Mann, Graham J., Marra, Marco A., Matejka, Brenna, Mayo, Michael, Mehrabi, Sousan, Meng, Shaowu, Meyerson, Matthew, Mieczkowski, Piotr A., Miller, John P., Miller, Martin L., Mills, Gordon B., Moiseenko, Fedor, Moore, Richard A., Morris, Scott, Morrison, Carl, Morton, Donald, Moschos, Stergios, Mose, Lisle E., Muller, Florian L., Mungall, Andrew J., Murawa, Dawid, Murawa, Pawel, Murray, Bradley A., Nezi, Luigi, Ng, Sam, Nicholson, Dana, Noble, Michael S., Osunkoya, Adeboye, Owonikoko, Taofeek K., Ozenberger, Bradley A., Pagani, Elena, Paklina, Oxana V., Pantazi, Angeliki, Parfenov, Michael, Parfitt, Jeremy, Park, Peter J., Park, Woong-Yang, Parker, Joel S., Passarelli, Francesca, Penny, Robert, Perou, Charles M., Pihl, Todd D., Potapova, Olga, Prieto, Victor G., Protopopov, Alexei, Quinn, Michael J., Radenbaugh, Amie, Rai, Kunal, Ramalingam, Suresh S., Raman, Ayush T., Ramirez, Nilsa C., Ramirez, Ricardo, Rao, Uma, Rathmell, W. Kimryn, Ren, Xiaojia, Reynolds, Sheila M., Roach, Jeffrey, Robertson, A. Gordon, Ross, Merrick I., Roszik, Jason, Russo, Giandomenico, Saksena, Gordon, Saller, Charles, Samuels, Yardena, Sander, Chris, Sander, Cindy, Sandusky, George, Santoso, Netty, Saul, Melissa, Saw, Robyn PM., Schadendorf, Dirk, Schein, Jacqueline E., Schultz, Nikolaus, Schumacher, Steven E., Schwallier, Charles, Scolyer, Richard A., Seidman, Jonathan, Sekhar, Pedamallu Chandra, Sekhon, Harmanjatinder S., Senbabaoglu, Yasin, Seth, Sahil, Shannon, Kerwin F., Sharpe, Samantha, Sharpless, Norman E., Shaw, Kenna R. Mills, Shelton, Candace, Shelton, Troy, Shen, Ronglai, Sheth, Margi, Shi, Yan, Shiau, Carolyn J., Shmulevich, Ilya, Sica, Gabriel L., Simons, Janae V., Sinha, Rileen, Sipahimalani, Payal, Sofia, Heidi J., Soloway, Matthew G., Song, Xingzhi, Sougnez, Carrie, Spillane, Andrew J., Spychała, Arkadiusz, Stretch, Jonathan R., Stuart, Joshua, Suchorska, Wiktoria M., Sucker, Antje, Sumer, S. Onur, Sun, Yichao, Synott, Maria, Tabak, Barbara, Tabler, Teresa R., Tam, Angela, Tan, Donghui, Tang, Jiabin, Tarnuzzer, Roy, Tarvin, Katherine, Tatka, Honorata, Taylor, Barry S., Teresiak, Marek, Thiessen, Nina, Thompson, John F., Thorne, Leigh, Thorsson, Vesteinn, Trent, Jeffrey M., Triche, Timothy J., Jr., Tsai, Kenneth Y., Tsou, Peiling, Van Den Berg, David J., Van Allen, Eliezer M., Veluvolu, Umadevi, Verhaak, Roeland G., Voet, Douglas, Voronina, Olga, Walter, Vonn, Walton, Jessica S., Wan, Yunhu, Wang, Yuling, Wang, Zhining, Waring, Scot, Watson, Ian R., Weinhold, Nils, Weinstein, John N., Weisenberger, Daniel J., White, Peter, Wilkerson, Matthew D., Wilmott, James S., Wise, Lisa, Wiznerowicz, Maciej, Woodman, Scott E., Wu, Chang-Jiun, Wu, Chia-Chin, Wu, Junyuan, Wu, Ye, Xi, Ruibin, Xu, Andrew Wei, Yang, Da, Yang, Liming, Yang, Lixing, Zack, Travis I., Zenklusen, Jean C., Zhang, Hailei, Zhang, Jianhua, Zhang, Wei, Zhao, Xiaobei, Zhu, Jingchun, Zhu, Kelsey, Zimmer, Lisa, Zmuda, Erik, and Zou, Lihua

Published
2015
Full Text
View/download PDF

50. Supplementary Methods from Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Author

Patrick Hwu, Audrey Gonzalez, Seth Wardell, Renjith Ramachandran, Christopher Toth, Orenthial J. Fulbright, Rahmatu Mansaray, Michael A. Davies, Janice N. Cormier, Richard Royal, Anthony Lucci, Jeffrey E. Gershenwald, Jeffrey E. Lee, Merrick I. Ross, Sapna Patel, Wen-Jen Hwu, Agop Bedikian, Jade Homsi, Kevin Kim, Nicholas Papadopoulos, Victor Prieto, Elizabeth Shpall, John D. McMannis, Valen E. Johnson, Michelle Glass, Gladys Alvarado, Sandy Mahoney, Gregory Lizee, Richard Wu, Jessica Chacon, Priscilla Miller, Patricia S. Fox, Minying Zhang, Chantale Bernatchez, and Laszlo G. Radvanyi

Abstract

PDF file - 115K

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results